ICD-10-CM 2027 diagnosis code
Z79.810Long term (current) use of selective estrogen receptor modulators (SERMs)
Z79.810 is a valid, billable ICD-10-CM code for long term (current) use of selective estrogen receptor modulators (serms). It can be reported on claims for dates of service from October 1, 2026 – September 30, 2027.Short description: Lng trm (crnt) use of slctv estrog receptor modulators
Code unchanged since ICD-10-CM took effect on October 1, 2015. Source: official FY2027 ICD-10-CM release from CDC/NCHS and CMS. Page updated September 29, 2026. About our data
About Z79.810
Z79.810 is the ICD-10-CM diagnosis code for long term (current) use of selective estrogen receptor modulators (SERMs). It belongs to category Z79 (long term (current) drug therapy), block Z77-Z99 (persons with potential health hazards related to family and personal history and certain conditions influencing health status) and chapter 21 (factors influencing health status and contact with health services). It is billable, so it can be reported on its own for dates of service from October 1, 2026 through September 30, 2027.
Within Z79.81 (long term (current) use of agents affecting estrogen receptors and estrogen levels), Z79.810 is specifically for long term (current) use of selective estrogen receptor modulators (SERMs). Related codes cover aromatase inhibitors (Z79.811) and other agents affecting estrogen receptors and estrogen levels (Z79.818).
It is not a CC or MCC, so as a secondary diagnosis it doesn't change the MS-DRG severity level.
In MS-DRG v44.0, it is part of the grouping logic for DRG 951 (Other Factors Influencing Health Status, relative weight 0.5577), in MDC 23 (Factors Influencing Health Status and Other Contacts with Health Services), as a principal or secondary diagnosis. The DRG a claim lands in depends on the principal diagnosis, procedures and any CC/MCC secondary diagnoses.
It is not acceptable as the principal diagnosis for an inpatient stay; it may be reported as a secondary diagnosis.
It is exempt from present-on-admission (POA) reporting, so no POA indicator is required.
It has been part of ICD-10-CM since the code set took effect on October 1, 2015 and hasn't changed since.
Before ICD-10, this condition was coded in ICD-9-CM as V07.51 (use of selective estrogen receptor modulators (SERMs)).
Coding notes
- Long term (current) use of raloxifene (Evista)
- Long term (current) use of tamoxifen (Nolvadex)
- Long term (current) use of toremifene (Fareston)
Notes that apply from higher levels
Instructions written at a parent level also apply to Z79.810.
› From Z79.81 Long term (current) use of agents affecting estrogen receptors and estrogen levels
- hormone replacement therapy (Z79.890)
Broader instructions also apply from Z77-Z99 Persons with potential health hazards related to family and personal history and certain conditions influencing health status and Chapter 21: Factors influencing health status and contact with health services.
Alphabetic index entries
14 entriesTerms in the official ICD-10-CM index that lead to Z79.810.
- Long-term (current) (prophylactic) drug therapy (use of) › Evista
- Long-term (current) (prophylactic) drug therapy (use of) › Fareston
- Long-term (current) (prophylactic) drug therapy (use of) › Nolvadex
- Long-term (current) (prophylactic) drug therapy (use of) › raloxifene (Evista)
- Long-term (current) (prophylactic) drug therapy (use of) › selective estrogen receptor modulators (SERMs)
- Long-term (current) (prophylactic) drug therapy (use of) › tamoxifen (Nolvadex)
- Long-term (current) (prophylactic) drug therapy (use of) › toremifene (Fareston)
- Therapy › drug, long-term (current) (prophylactic) › Evista
- Therapy › drug, long-term (current) (prophylactic) › Fareston
- Therapy › drug, long-term (current) (prophylactic) › Nolvadex
- Therapy › drug, long-term (current) (prophylactic) › raloxifene (Evista)
- Therapy › drug, long-term (current) (prophylactic) › selective estrogen receptor modulators (SERMs)
- Therapy › drug, long-term (current) (prophylactic) › tamoxifen (Nolvadex)
- Therapy › drug, long-term (current) (prophylactic) › toremifene (Fareston)
MS-DRG v44.0 grouping
All DRGs →Inpatient MS-DRGs this diagnosis can group to, as the principal or a secondary diagnosis, depending on the rest of the claim.
MDC 23 · Factors Influencing Health Status and Other Contacts with Health Services
ICD-9-CM equivalent
Converter →- V07.51Use of selective estrogen receptor modulators (SERMs)exact
From the CMS 2018 General Equivalence Mappings (GEMs), the final GEMs release.
Code history
- 2016
- 2017
- 2018
- 2019
- 2020
- 2021
- 2022
- 2023
- 2024
- 2025
- 2026
- 2027
- FY2016 (effective 10/1/2015): Added (first year of ICD-10-CM)
- No changes since FY2016.
Common questions about Z79.810
Is Z79.810 billable?
- Yes. Z79.810 is a billable/specific ICD-10-CM code valid for FY2027 (October 1, 2026 – September 30, 2027).
Can Z79.810 be used as a principal diagnosis?
- No. It is not acceptable as the principal diagnosis for an inpatient stay; it may be reported as a secondary diagnosis.
Is Z79.810 a CC or MCC?
- No. Z79.810 is neither a CC nor an MCC under MS-DRG v44.0.
What DRG does Z79.810 group to?
- Z79.810 is used in the MS-DRG v44.0 logic for MS-DRG 951 (Other Factors Influencing Health Status). Which one applies depends on whether it is the principal diagnosis and on the rest of the claim.
What is the ICD-9 code for Z79.810?
- The CMS General Equivalence Mappings map Z79.810 to ICD-9-CM V07.51.